Creating Social Value

Our initiatives

• Quality and food safety management systems established for all business units, aligned with ISO 13485, ISO 9001, FSSC 22000, and GMP standards
• Quality risk management system in place, supported by product safety risk assessments and preventive quality investigations
• Quality control laboratories deployed globally to ensure product consistency and compliance through release testing and stability studies
• Conduct regular quality inspections and audits across all business units, and undergo third-party quality audits, client audits, and regulatory inspections
• Perform desktop, on-site, and remote quality audits on suppliers, and implement quality supervision, training and improvement programs
• Regularly organize quality training for all employees, covering quality management systems, and manufacturing expertise, specialized training for key projects, as well as third-party training
• Collect and respond to client feedback and concerns through multiple channels, with the overall satisfaction score increased to 93.69%

Our targets

• Zero child labor, forced labor or other illegal employment issues
• 100% of employees trained on anti-discrimination and anti-harassment
• At least 50% female representation in our global workforce and at least 45% in managerial positions
• Individual development plans covering 100% of employees
• Occupational health and safety inspections and training covering 100% of our operational sites

Our initiatives

• Talent Acquisition: Expand our global talent pool through campus recruitment, social hiring, internal mobility, and internal referral
• Human Rights Protection: Adopt a zero-tolerance approach to discrimination, harassment, forced labor, and child labor, identify, assess, and mitigate human rights risks, and provide training and reporting channels
• Talent Development: Provide diverse training and development opportunities and competitive compensation and incentives
• Talent Pipeline Strategy: Develop a robust talent pipeline through talent review, mentorship, and internal mobility programs
• Employee Engagement: Offer comprehensive benefits, organize cultural events, support women’s growth, and maintain open communication channels
• Occupational Health and Safety: Improve inherently safer design, conduct safety risk identification and assessments, and enhance ongoing risk monitoring by all employees to mitigate safety hazards

Performance highlights

• 100% employees with professional training
• 49.6% women in managerial positions
• 43.3% women in top executive positions
• 56.9% women in STEM-related positions
• 33 average training hours
• 91.6% employee satisfaction

Environmental benefits

Social benefits

• GenGenius™ redefines productivity in gene synthesis: GenScript’s GenGenius™ automated platform streamlines the entire gene synthesis workflow—from DNA synthesis and seamless cloning to standard 4µg plasmid preparation. By integrating end-to-end automation with real-time quality monitoring, the platform drastically compresses R&D timelines. Driven by this technological edge, our FLASH Gene service sets a new industry benchmark with 4-business-day "gene-to-plasmid" delivery, providing the scalable throughput needed to propel global breakthroughs in antibody therapeutics, vaccines, and CGT.
• AmMag™ Quatro Mini-1100 transforms plasmid DNA purification: AmMag™ Quatro Mini-1100 revolutionizes plasmid DNA purification with its fully automated, high-throughput, and scalable design. Supporting up to 192 samples per run and delivering high-purity, low-endotoxin transfection-ready plasmid DNA, it enhances efficiency and consistency for gene therapy research, vaccine development, and synthetic biology. This innovative solution expands our automated product portfolio, empowering global researchers with flexible, reliable tools to accelerate life science breakthroughs.
• CytoSinct™ platform empowers IND approvals of cell therapies: GenScript’s CytoSinct™ cell isolation platform offers high-quality cell isolation magnetic nanobeads, activation reagents, consumables and instruments for cell therapies. In 2025, the platform supported multiple customers in securing Investigational New Drug (IND) approvals from the U.S. FDA and the National Medical Products Administration (NMPA), including a cell therapy for malignant tumors, an allogeneic universal CAR-T cell injection for B‑cell acute lymphoblastic leukemia, a CAR‑NK cell therapy, an autologous TCR‑T cell therapy candidate for solid tumors, and an off‑the‑shelf CAR‑T cell injection for adult relapsed/refractory B‑ALL.
• GMP sgRNA expedites IND approvals of cell therapies: With 23 years of expertise, GenScript offers comprehensive nucleic acid synthesis services, including R&D to GMP-grade sgRNA and knock-in templates. Our sgRNA offers high editing efficiency, low toxicity, and minimal off-target effects. Additionally, Our sgRNA is provided with drug master files (DMF) to accelerate IND submissions and clinical trials. As of the end of 2025, we supported over 50 regulatory filings and 22 global IND approvals. This track record underscores our superior quality, rigorous process control, and strong regulatory expertise in the U.S. and China, enabling accelerated development of cell therapies.
• ExpressCMC™ service fast-tracks DNA to IND: Our subsidiary ProBio launched an mAb and bsAb superfast ExpressCMC™ service, which transforms DNA sequences into GMP clinical drug product with unmatched speed. It enables Tox batch production completion in just 4 months and GMP drug product release in just nine months. This industry-leading timeline is driven by our proprietary ProMax™ vector, which is high-yield and exceptionally stable, enabling the earliest possible identification of top clones and an early start of Tox batch manufacturing. This service significantly accelerates development timelines while maintaining the highest standards of quality.
• PD-1 NME drives breakthroughs in next-generation immunotherapies: ProBio licensed its anti-PD-1 NME to LaNova Medicines, enabling the development of the PD-1/VEGF bispecific antibody LM-299. Merck’s partnership with LaNova further validates the potential of this innovative approach. Our anti-PD-1 single-domain antibody is a key next-generation cancer treatment.
• Mellia™ Brazzein sweet protein unlocks new potential sugar reduction innovation: In 2025, GenScript’s subsidiary Bestzyme received Generally Recognized as Safe (GRAS) approval from the U.S. Food and Drug Administration (FDA) for its Mellia™ Brazzein sweet protein. This milestone affirms its safety and regulatory compliance. Bestzyme enabled sustainable and industrial-scale production of Brazzein through precision fermentation. This product brings a leading protein solution for global sugar-reduction applications in the food and beverage industry.